Metastatic Breast Cancer

Immediate Subsequent lines of therapy after T-DXd in Metastatic Breast Cancer – Dana-Farber’s Breast Oncology Center

Dana-Farber’s Breast Oncology Center shared a post on X:

“SABCS24 POSTER SESSION | P1-08-08 |

Real-world efficacy of immediate subsequent lines of therapy after trastuzumab deruxtecan (T-DXd) in patients with Metastatic Breast Cancer (MBC) – retrospective study from the nationwide Flatiron database.”

Immediate Subsequent lines of therapy after T-DXd in Metastatic Breast Cancer - Dana-Farber’s Breast Oncology Center

breast oncology cancer Center Dana-Farber’s Breast Oncology Center fight against cancer Global fight against cancer MBC metastatic breast cancer OncoDaily Oncology SABCS24 T-Dxd Trastuzumab deruxtecan